{rfName}
Pe

Indexed in

License and use

Icono OpenAccess

Citations

2

Altmetrics

Impact on the Sustainable Development Goals (SDGs)

Analysis of institutional authors

Espinosa EAuthor

Share

October 15, 2024
Publications
>
Article
Hybrid Gold

Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study.

Publicated to:AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 25 (6): 987-996 - 2024-10-08 25(6), DOI: 10.1007/s40257-024-00885-w

Authors: Laurent Mortier; Lisa Villabona; Ben Lawrence; Ana Arance; Marcus O. Butler; M. Beylot‐Barry; Philippe Saïag; Mahtab Samimi; Paolo A. Ascierto; Francesca Spada; Michel De Pontville; Michele Maio; Alfonso Berrocal; Enrique Espinosa; Jaume Capdevila; Max Levin; Debasmita Das; Clemens Krepler; Dmitri Grebennik; Vanna Chiarion‐Sileni

Affiliations

Centre Hospitalier Universitaire de Bordeaux, INSERM 1312, 1 Rue Jean Burguet, Bordeaux, France. - Author
Centre Hospitalier Universitaire de Caen-Hôpital Côte de Nacre, Av. de la Côte de Nacre CS 30001, Caen, France. - Author
Departments of Medicine and Immunology, University of Toronto, 610 University Avenue, Toronto, ON, Canada. - Author
Hôpital Ambroise Paré, APHP & EA4340, University of Versailles-SQY, and Paris-Saclay University, 9 Av. Charles de Gaulle, Boulogne-Billancourt, France. - Author
Hospital Clinic Barcelona and IDIBAPS, C. de Villarroel, 170, Barcelona, Spain. - Author
Hospital General Universitario de Valencia, Avda. Tres Cruces, 2, Valencia, Spain. - Author
Istituto Europeo di Oncologia (IEO) IRCCS, Via Giuseppe Ripamonti, 435, Milan, Italy. - Author
Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Via Mariano Semmola, 53, Naples, Italy. - Author
Istituto Oncologico Veneto IOV-IRCCS, Via Gattamelata, 64, Padua, Italy. - Author
Karolinska University Hospital, Akademiska stråket 13, G4:04, 17176, Stockholm, Sweden. - Author
Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, USA. - Author
Service of Oncology, Hospital Universitario La Paz, Universidad Autónoma de Madrid - CIBERONC, P. Castellana, 261-Madrid, Spain. - Author
Université Lille, CHRU Lille, 42 Rue Paul Duez, Lille, France. laurent.mortier@chru-lille.fr. - Author
University of Auckland, 85 Park Rd, Auckland City Hospital 2 Park Rd, Auckland, New Zealand. - Author
University of Gothenburg and Sahlgrenska University Hospital, Universitetsplatsen 1, Gothenburg, Sweden. - Author
University of Siena and Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy. - Author
University of Tours, France; ISP1282 INRA University of Tours, 60 Rue du Plat d'Étain, Tours, France. - Author
Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Pg. de la Vall d'Hebron, 119, Barcelona, Spain. - Author
See more

Abstract

The phase III KEYNOTE-913 study was conducted to evaluate the efficacy and safety of pembrolizumab as first-line therapy in patients with advanced Merkel cell carcinoma (MCC). The aim was to report results from the primary analysis of KEYNOTE-913. Patients with recurrent locally advanced or metastatic MCC received pembrolizumab 200 mg intravenously every 3 weeks for up to 35 treatments (~ 2 years). The primary end point was objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) by blinded independent central review (BICR). Secondary end points were duration of response (DOR) and progression-free survival (PFS) per RECIST v1.1 by BICR, overall survival (OS), and safety and tolerability. Fifty-five patients were treated with pembrolizumab. The median time from first dose to data cutoff (February 15, 2024) was 50.3 months (range 38.7-59.4). The ORR was 49% (95% confidence interval [CI] 35-63), with 12 complete responses and 15 partial responses. The median DOR was 39.8 months (range 4.8-52.5+), and the 24-month DOR rate was 69%. The median PFS was 9.3 months (95% CI 3-26), and the 24-month PFS rate was 39%. The median OS was 24.3 months (95% CI 12.4 to not reached), and the 24-month OS rate was 51%. Any-grade treatment-related adverse events (AEs) occurred in 38 patients (69%); 13 patients (24%) experienced grade 3-5 AEs. The most common treatment-related AEs were fatigue (n = 12 [22%]), pruritus (n = 12 [22%]), and lipase increase (n = 10 [18%]). One patient died of treatment-related Guillain-Barré syndrome. Pembrolizumab provided durable antitumor activity and promising survival and had a manageable safety profile in patients with recurrent locally advanced or metastatic MCC, supporting its use in this population. Clinicaltrials.gov, NCT03783078.

Keywords

DermatologyGeneral medicineMedicina iMedicina iiMedicine (miscellaneous)

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal AMERICAN JOURNAL OF CLINICAL DERMATOLOGY due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 5/96, thus managing to position itself as a Q1 (Primer Cuartil), in the category Dermatology. Notably, the journal is positioned above the 90th percentile.

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-10-25:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 7.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 7 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 5.95.
  • The number of mentions on the social network Facebook: 1 (Altmetric).
  • The number of mentions on the social network X (formerly Twitter): 10 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
Continuing with the social impact of the work, it is important to emphasize that, due to its content, it can be assigned to the area of interest of ODS 3 - Ensure healthy lives and promote well-being for all at all ages, with a probability of 78% according to the mBERT algorithm developed by Aurora University.